EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study

Yael Eshet iD, Liran Domachevsky, Noam Tau, Gregory Peters Founshtein, Michal Eifer, Jair Bar, Iris Eshed

PLOS One · 2026

DOI: 10.1371/journal.pone.0333223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yael Eshet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Crizotinib, Carcinoma, Non-Small-Cell Lung, Protein-Tyrosine Kinases, Anaplastic Lymphoma Kinase. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Progressive arthropathy was anecdotally described in patients exposed to crizotinib, a receptor tyrosine kinases inhibitor (TKI) used to treat anaplastic lymphoma kinase (ALK) or ROS Proto-Oncogene 1 (ROS1) positive non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence of this adverse effect.

Methods

We retrospectively evaluated imaging studies of all patients in our institution receiving TKI for ALK-rearranged or ROS1-positive NSCLC (crizotinib, alectinib, lorlatinib, brigatinib).

Results

Between February 2012 and August 2023, out of a total number of 71 subjects (51% male, 36−88 years old) who received TKI’s for ALK-rearranged/ ROS1 positive NSCLC, 34/71 (47%) were exposed at least once to crizotinib treatment, while the other 37/71 (53%) patients received other TKI’s. Significantly higher incidence (p = 0.02) of irreversible, progressive arthropathy in one or more joints was detected in 18% (6/34, 95% CI: 0.1–0.26) of crizotinib-treated patients, up to 6 years after treatment initiation. Imaging findings included synovial proliferation and progressive arthropathy in hip and shoulder joints, and vertebral endplate destruction.

Conclusion

We found progressive arthropathy, mostly painless, in one or more joints or intervertebral spaces of patients receiving crizotinib for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibCarcinoma, Non-Small-Cell LungProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseLung NeoplasmsProtein Kinase InhibitorsProto-Oncogene ProteinsHumansMaleAgedRetrospective StudiesFemaleProto-Oncogene MasAdultMiddle AgedAged, 80 and overGene RearrangementPiperidinesAminopyridinesLactamsPyrazoles

Substanzen

CrizotinibProto-Oncogene MasProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseMAS1 protein, humanALK protein, humanProtein Kinase InhibitorsROS1 protein, humanProto-Oncogene Proteinslorlatinib

Autor:innen und Institutionen

  • Department of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.
  • Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
  • Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Yael Eshet

Zitieren

APA

Eshet, Y., Domachevsky, L., Tau, N., Founshtein, G. P., Eifer, M., Bar, J., & Eshed, I. (2026). Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study. PLOS One. https://doi.org/10.1371/journal.pone.0333223

Vancouver

Eshet Y, Domachevsky L, Tau N, Founshtein GP, Eifer M, Bar J, et al. Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study. PLOS One. 2026. doi:10.1371/journal.pone.0333223

BibTeX
@article{Eshet2026,
  author = {Eshet, Yael and Domachevsky, Liran and Tau, Noam and Founshtein, Gregory Peters and Eifer, Michal and Bar, Jair and Eshed, Iris},
  title = {Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0333223}
}
Kostenlos starten →